Please Wait
Applying Filters...
menu
    • menu
    IOL Chemicals is an innovation-driven bulk drug, Intermediate and Specialty Chemicals company.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Cyclophosphamide Monohydrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 1,033Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    ENHERTU® Preceded By THP Yields 67% Pathologic Response
    ENHERTU® Preceded By THP Yields 67% Pathologic Response

    18 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251018622942/en/ENHERTU-fam-trastuzumab-deruxtecan-nxki-followed-by-THP-before-surgery-resulted-in-a-pathologic-complete-response-in-67-of-patients-with-high-risk-HER2-positive-early-stage-breast-cancer-in-DESTINY-Breast11-Phase-III-trial

    BUSINESSWIRE
    18 Oct 2025
    Share Share
    Allogene advances FC lymphodepletion in ALPHA3 trial
    Allogene advances FC lymphodepletion in ALPHA3 trial

    01 Aug 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/08/01/3125763/0/en/Allogene-Therapeutics-Moves-Forward-with-Standard-Fludarabine-and-Cyclophosphamide-FC-Lymphodepletion-Regimen-in-the-ALPHA3-Trial-for-Cemacabtagene-Ansegedleucel-Cema-Cel-in-First-.html

    GLOBENEWSWIRE
    01 Aug 2025
    Share Share
    Nexus Wins Patent Litigation for Injectable Cyclophosphamide
    Nexus Wins Patent Litigation for Injectable Cyclophosphamide

    28 May 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250528703755/en/Nexus-Wins-Patent-Litigation-for-Injectable-Cyclophosphamide-Paving-Way-for-Generic

    BUSINESSWIRE
    28 May 2025
    Share Share
    Genentech’s Polivy Combo is New Standard for Untreated Lymphoma
    Genentech’s Polivy Combo is New Standard for Untreated Lymphoma

    09 Dec 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20241208818007/en

    BUSINESSWIRE
    09 Dec 2024
    Share Share
    Fate Therapeutics Reports Q2 2024 Results And Business Updates
    Fate Therapeutics Reports Q2 2024 Results And Business Updates

    13 Aug 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/08/13/2929617/24675/en/Fate-Therapeutics-Reports-Second-Quarter-2024-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    13 Aug 2024
    Share Share
    Enforcement Report - Week of April 10, 2024
    Enforcement Report - Week of April 10, 2024

    10 Apr 2024

    // FDA

    https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-10-2024-2074.pdf

    FDA
    10 Apr 2024
    Share Share